{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:24:19Z","timestamp":1790688259500,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CHU de La R\u00e9union"},{"name":"University of La R\u00e9union"},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The transition to metabolically unhealthy obesity (MUO) is driven by the limited expandability of adipose tissue (AT). Familial Partial Lipodystrophy type 2 (FPLD2) is an alternative model for AT dysfunction that is suitable for comparison with obesity. While MUO is associated with low-grade systemic inflammation, studies of inflammation in FPLD2 have yielded inconsistent results. Consequently, comparison of inflammation markers between FPLD2 and obesity is of great interest to better understand the pathophysiological defects of FPLD2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the levels of inflammatory biomarkers between a population of patients with FPLD2 due to the same \u2018Reunionese\u2019 <jats:italic>LMNA<\/jats:italic> variant and a population of patients with obesity (OB group).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adiponectin, leptin, IL-6, TNF-\u03b1 and MCP-1 plasma levels were measured by enzyme-linked immuno assays for 60 subjects with FPLD2 and for 60 subjects with obesity. The populations were closely matched for age, sex, and diabetic status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Metabolic outcomes were similar between the two populations. Adiponectinemia and leptinemia were lower in the FPLD2 group than in the OB group (p\u2009&lt;\u20090.01 for both), while MCP-1 levels were higher in the FPLD2 than in the OB group (p\u2009&lt;\u20090.01). Levels of other inflammatory markers were not significantly different.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Insulin-resistant patients with FPLD2 and obesity share common complications related to AT dysfunction. Inflammatory biomarker analyses demonstrated that MCP-1 levels and adiponectin levels differ between patients with FPLD2 and patients with obesity. These two AT pathologies thus appear to have different inflammatory profiles.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-023-01055-4","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T03:29:35Z","timestamp":1682047775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Familial partial lipodystrophy type 2 and obesity, two adipose tissue pathologies with different inflammatory profiles"],"prefix":"10.1186","volume":"15","author":[{"given":"Guillaume","family":"Treiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Gonthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Guilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Medjane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriane","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Cogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Meilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Nobecourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"issue":"7","key":"1055_CR1","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793\u2013801.","journal-title":"J Clin Invest"},{"issue":"4","key":"1055_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5114\/aoms.2016.58928","volume":"13","author":"MS Ellulu","year":"2017","unstructured":"Ellulu MS, Patimah I, Khaza\u2019ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851\u201363.","journal-title":"Arch Med Sci"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","volume":"69","author":"HS Park","year":"2005","unstructured":"Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005;69:29\u201335.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"1055_CR4","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1172\/JCI26498","volume":"116","author":"H Kanda","year":"2006","unstructured":"Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa KI, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116(6):1494\u2013505.","journal-title":"J Clin Invest"},{"key":"1055_CR5","doi-asserted-by":"crossref","unstructured":"Shackleton S, Lloyd DJ, Jackson SNJ et al. LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy. Nature Genetics. 2000;24:153\u2013156.","DOI":"10.1038\/72807"},{"issue":"9","key":"1055_CR6","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3390\/cells9091947","volume":"9","author":"AA Varlet","year":"2020","unstructured":"Varlet AA, Helfer E, Badens C. Molecular and mechanobiological pathways related to the physiopathology of FPLD2. Cells. 2020;9(9):1947.","journal-title":"Cells"},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/19491034.2015.1050568","volume":"6","author":"T Sieprath","year":"2015","unstructured":"Sieprath T, Corne TDJ, Nooteboom M, et al. Sustained accumulation of prelamin A and depletion of lamin A\/C both cause oxidative stress and mitochondrial dysfunction but induce different cell fates. Nucleus. 2015;6:236\u201346.","journal-title":"Nucleus"},{"issue":"12","key":"1055_CR8","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s00125-005-0038-x","volume":"48","author":"SP Wong","year":"2005","unstructured":"Wong SP, Huda M, English P, et al. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A\/C. Diabetologia. 2005;48(12):2641\u20139.","journal-title":"Diabetologia"},{"issue":"1","key":"1055_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/01.ATV.0000047460.27435.B8","volume":"23","author":"RA Hegele","year":"2003","unstructured":"Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A\/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol. 2003;23(1):111\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13098-017-0301-6","volume":"10","author":"MC Foss-Freitas","year":"2018","unstructured":"Foss-Freitas MC, Ferraz RC, Monteiro LZ, et al. Endoplasmic reticulum stress activation in adipose tissue induces metabolic syndrome in individuals with familial partial lipodystrophy of the Dunnigan type. Diabetol Metab Syndr. 2018;10:6.","journal-title":"Diabetol Metab Syndr"},{"key":"1055_CR11","doi-asserted-by":"crossref","unstructured":"Bidault G, Garcia M, Vantyghem MC, et al. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2162\u201371.","DOI":"10.1161\/ATVBAHA.113.301933"},{"key":"1055_CR12","doi-asserted-by":"crossref","unstructured":"Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002 May;87(5):2395.","DOI":"10.1210\/jcem.87.5.8624"},{"key":"1055_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","volume":"9","author":"H Cao","year":"2000","unstructured":"Cao H, Hegele RA. Nuclear lamin A\/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000;9:109\u201312.","journal-title":"Hum Mol Genet"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","volume":"45","author":"M Kwapich","year":"2019","unstructured":"Kwapich M, Lacroix D, Espiard S, et al. Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype\u2013genotype correlation. Diabetes and Metabolism. 2019;45:382\u20139.","journal-title":"Diabetes and Metabolism"},{"issue":"4","key":"1055_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/EJE-21-0282","volume":"185","author":"G Treiber","year":"2021","unstructured":"Treiber G, Flaus Furmaniuk A, Guilleux A, et al. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. Eur J Endocrinol. 2021;185(4):453\u201362.","journal-title":"Eur J Endocrinol"},{"key":"1055_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1210\/jc.2010-2234","volume":"96","author":"C Le Dour","year":"2011","unstructured":"Le Dour C, Schneebeli S, Bakiri F, et al. A homozygous mutation of prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin-A. J Clin Endocrinol Metab. 2011;96:856\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/cc10021","volume":"15","author":"K Robinson","year":"2011","unstructured":"Robinson K, Prins J, Venkatesh B. Clinical review: Adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011;15:221.","journal-title":"Crit Care"},{"issue":"1","key":"1055_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1559-4572.2008.00030.x","volume":"4","author":"J Kawano","year":"2009","unstructured":"Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009;4(1):44\u20139.","journal-title":"J Cardiometab Syndr"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/90984","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941\u20136.","journal-title":"Nat Med"},{"issue":"6","key":"1055_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3892\/ijmm_00000302","volume":"24","author":"E Zoico","year":"2009","unstructured":"Zoico E, Garbin U, Olioso D, et al. The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3-L1 adipocytes: role of the NF-kB pathway. Int J Mol Med. 2009;24(6):847\u201351.","journal-title":"Int J Mol Med"},{"issue":"11","key":"1055_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.5551\/jat.58875","volume":"28","author":"M Fujita","year":"2021","unstructured":"Fujita M, Yamamoto H, Yoshida N, Ono R, Matsuoka T, Kihara S. Atheroprotective roles of Adiponectin via CCL2 inhibition. J Atheroscler Thromb. 2021;28(11):1204\u201313.","journal-title":"J Atheroscler Thromb"},{"key":"1055_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.atherosclerosis.2010.09.012","volume":"213","author":"YH Lee","year":"2010","unstructured":"Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis. 2010;213:592\u20137.","journal-title":"Atherosclerosis"},{"key":"1055_CR23","doi-asserted-by":"publisher","unstructured":"Treiber G, Guilleux A, Huynh K, Bonfanti O, Flaus-Furmaniuk A, Couret D, Mellet N, Bernard C, Le-Moullec N, Doray B, J\u00e9ru I, Maiza JC, Domun B, Cogne M, Meilhac O, Vigouroux C, Meikle PJ, Nob\u00e9court E. Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes. Diabetes Metab. 2022 Nov 15;49(2):101409. https:\/\/doi.org\/10.1016\/j.diabet.2022.101409. Epub ahead of print. PMID: 36400409.","DOI":"10.1016\/j.diabet.2022.101409"},{"issue":"8","key":"1055_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570\u20138.","journal-title":"N Engl J Med"},{"key":"1055_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/obr.12242","volume":"16","author":"Y Bai","year":"2015","unstructured":"Bai Y, Sun Q. Macrophage recruitment in obese adipose tissue. Obes Rev. 2015;16:127\u201336.","journal-title":"Obes Rev"},{"key":"1055_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1079\/BJN20041213","volume":"92","author":"P Trayhurn","year":"2004","unstructured":"Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347\u201355.","journal-title":"Br J Nutr"},{"key":"1055_CR27","doi-asserted-by":"crossref","unstructured":"Katherine Esposito A, Pontillo F, Giugliano G, Giugliano R, Marfella G, Nicoletti D, Giugliano. Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women, The Journal of Clinical Endocrinology & Metabolism, Volume\u00a088, Issue 3, 1 March 2003, Pages 1055\u20131058.","DOI":"10.1210\/jc.2002-021437"},{"key":"1055_CR28","doi-asserted-by":"publisher","unstructured":"Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne). 2013;3:181. Published 2013 Jan 8. https:\/\/doi.org\/10.3389\/fendo.2012.00181","DOI":"10.3389\/fendo.2012.00181"},{"key":"1055_CR29","doi-asserted-by":"publisher","unstructured":"Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006 Feb;7(2):85\u201396. https:\/\/doi.org\/10.1038\/nrm1837. PMID: 16493415.","DOI":"10.1038\/nrm1837"},{"key":"1055_CR30","doi-asserted-by":"crossref","unstructured":"Berger S, Ceccarini G, Scabia G, Barone I, Pelosini C, Ferrari F, Magno S, Dattilo A, Chiovato L, Vitti P, Santini F, Maffei M. Lipodystrophy and obesity are associated with decreased number of T cells with regulatory function and pro-inflammatory macrophage phenotype. Int J Obes (Lond). 2017 Nov;41(11):1676\u201384.","DOI":"10.1038\/ijo.2017.163"},{"key":"1055_CR31","doi-asserted-by":"crossref","unstructured":"Herrero L, Shapiro H, Nayer A, Lee J, Shoelson SE. Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):240\u20135.","DOI":"10.1073\/pnas.0905310107"},{"key":"1055_CR32","doi-asserted-by":"crossref","unstructured":"Park SY, Gautier JF, Chon S. Assessment of insulin secretion and insulin resistance in human. Diabetes Metab J. 2021 Sep;45(5):641\u201354.","DOI":"10.4093\/dmj.2021.0220"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01055-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T03:30:39Z","timestamp":1682047839000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01055-4","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consents for molecular analyses and the study which has been approved by the Institutional Ethical Committee of Sud Mediterranee IV, France, has been performed according to local and European Union ethical rules (N\u00b0ID-RCB: 2021-A00105-36).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}